

ORAL PRESENTATIONS

[ID-O#116] Intramuscular versus intravenous naloxone for the reversal of methadone overdose: A randomized clinical trial

Ali Jangjou^a, Ali-Asghar Kolahi^b, Mahbobeh Taheri^c, Niloofar Deravi^d, Rebecca McDonald^c, Nicolas Buckley^f and Hossein Hassanian Moghaddam^g ^aDepartment of Emergency Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran; ^sSocial Determinants of Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ^{(Department of Community Medicine, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ^{(School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ^{(School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ^{(School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ^{(School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ^{(School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ^{(School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ^{(School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ^{(School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ^{(School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ^{(School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ^{(School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; ^{(School of Medicine, Shahid Beheshti University of Oslo, Oslo, Norway; ^{(Clinical Pharmacology, Sydney Pharmacy School, University of Sydney, Sydney, Australia; ^(Shahid School of Medicine, Shahid Beheshti University of Medical Sciences, Perth, Australia)}}}}}}}}}}}}}}

Background: Overdoses from long-acting opioids require ongoing antagonist administration, but the optimal route is not established

Objective: To compare the effectiveness of intramuscular (IM) versus intravenous (IV) naloxone in methadoneoverdose patients.

Methods: A single-center randomized trial was conducted with patients aged 19-59. After basic life support and an initial IV naloxone bolus, patients received either IM or IV naloxone. In the

IV group, about two-thirds of the effective dose was administered hourly. In the IM group, the dose was adjusted every 4 hours based on the calculated hourly requirement: 0.4 mg, 0.8 mg, 1.2 mg, or 1.6 mg, depending on the hourly need (<0.2 mg/h, 0.2- 0.4 mg/h, 0.4-0.6 mg/h, or >0.6 mg/h, respectively). Naloxone dosing adjustments were guided by arterial blood gas analysis and consciousness levels. Response rates and withdrawal symptoms were monitored during hospitalization.

Results: Of 160 patients with methadone overdose,

10 were excluded due to withdrawal syndrome post-ED naloxone administration. Groups were comparable in sex, drug use history, pre-hospital naloxone use, and overdose profile. The IM group had a lower median [IQR] methadone overdose compared to the IV group (50 [40, 95] vs. 80 [50, 100] mg). In the ED, full response rates to naloxone were similar between the IM (50.8%) and IV (49.2%) groups (p>0.05), with the remainder showing partial response. After the first dose, IM naloxone resulted in a significantly lower median [IQR] pulse rate change (-4 [-10, 0.5] vs. 6 [-0.5, 13] in IV). Oxygen saturation and pCO₂ levels were similar between groups. Withdrawal symptoms, assessed by COWS criteria, were significantly higher in the IV group. The IM group required less naloxone (4.1 [2.4, 6.8] vs.11.0 [4.4, 20.4] mg) during hospitalization.

Conclusion: IM and IV naloxone were equally effective for methadone overdose. However, IM naloxone caused fewer withdrawal symptoms and may be more accessible, making it a potential standard treatment in emergency departments.